MoCRA Check-In: EAS Consulting's John Bailey On Proposed Cosmetics Office Move
Executive Summary
John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group and former director of the US FDA's cosmetics office, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the Modernization of Cosmetic Regulations Act of 2022. Here he discusses the FDA's plan to move cosmetics regulation out of CFSAN and into the Office of the Chief Scientist.
You may also be interested in...
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.